Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
A phase 2 trial of Lutetium-177 vipivotide tetraxetan in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function is a phase 2 interventional study registered as NCT06004661 by Novartis Pharmaceuticals, with 23 participants enrolled, started 2024-04-04 and due to reach its primary completion in 2026-12-14. Interventions recorded: AAA617, 68Ga-PSMA-11. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Shares Novartis, Metastatic castration-resistant prostate cancer, Lutetium-177 vipivotide tetraxetan, Prostate cancer.
- TrialONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Shares Metastatic castration-resistant prostate cancer, Lutetium-177 vipivotide tetraxetan, Prostate cancer, Lutetium-177.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Metastatic castration-resistant prostate cancer, Gallium-68, Prostate cancer, Lutetium-177.
- TrialA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Gallium-68, Prostate cancer, Lutetium-177.
- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares Novartis, Gallium-68, Prostate cancer, Lutetium-177.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.